For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

Issuers still hold the key role in fighting fraud without compromising customer experience. A proactive issuer strategy ...

Check the time stamp on this data. Updated AI-Generated Signals for Centerpoint Energy Inc (holding Co) (CNP) available here: ...

Ascendis' TransCon CNP showed similar efficacy to BioMarin's Voxzogo but offers once-weekly dosing. Learn more on BMRN and ...

Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia ...

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by ...

CenterPoint Energy Inc. closed $3.40 short of its 52-week high ($31.57), which the company achieved on June 21st.

CNP Vita Assicura, a subsidiary of CNP Assurances, has entrusted Ostrum Asset Management with a €15.6 billion asset ...

(RTTNews) - Ascendis Pharma A/S (ASND) Monday said the pivotal ApproaCH study of TransCon CNP, in children with achondroplasia met its primary goal. The company's shares were more than 17 percent up ...

In a report released yesterday, David Lebovitz from Citi maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a ...

CNP Vita Assicura, a subsidiary of CNP Assurances, has entrusted Ostrum Asset Management with a €15.6 billion asset management mandate following a competitive tender. The partnership covers fixed ...

Wells Fargo has recently reduced CenterPoint Energy Inc (CNP) stock to Equal Weight rating, as announced on August 13, 2024, according to Finviz. Earlier, on August 2, 2024, KeyBanc Capital Markets ...